Supportive evidence of Foretinib’s anti-tumor activity through inhibition of c-Met- and VEGFR-2-mediated signal transduction was also demonstrated in further tumor models e.g. hepatocellular carcinoma [100], kidney cell carcinoma [101] and gastric carcinoma [102]. The gene discussed is MET; the disease is neoplasm.